United States (Change Country)AZD7762 Chemical Structure
AZD7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively. It significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. [1] [2]
[1] Cancer Res 2010;70:4972-4981
[2] Mol Cancer Ther 2008;7:2955-2966
| Molecular Weight (WM): | 362.42 |
|---|---|
| Formula: | C17H19FN4O2S |
| Solubility(R.T.:25°C): | DMSO 50mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
;Cancer Discovery, 2012, 2, 524-539 AZD7762 purchased from Selleck
Data from [Cancer Biol Ther 2012;13] AZD7762 purchased from Selleck
Data from [Cancer Biol Ther 2012;13] AZD7762 purchased from Selleck
;Cancer Biol Ther, 2011, 12(3), 215-28 AZD7762 purchased from Selleck
;Cancer Biol Ther, 2011, 12(3), 215-28. AZD7762 purchased from Selleck
;Cancer Discov, 2012, 2(6), 524-39. AZD7762 purchased from Selleck
;Cancer Discov, 2012, 2(6), 524-39. AZD7762 purchased from Selleck
Keywords:buy AZD7762 | AZD7762 supplier | purchase AZD7762 | AZD7762 cost | AZD7762 manufacturer | order AZD7762 | AZD7762 distributor